Prelude reports Q3 2026 results, advances KAT6A and JAK2V617F programsNov 16Quarterly updateLeonaBioPrelude Therapeutics Incorporated
Lilly posts galunisertib PFS results in prostate cancer; registers new bimagrumab HFpEF trialNov 6Weekly roundup, 7 itemsbimagrumabEli LillyUpdated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials updateSep 25Weekly roundup, 6 itemsabemaciclibbrenipatide
FDA approves supplemental application for Eli Lilly's InluriyoSep 18Regulatory decisionEli Lillyimlunestrant